Bernard Massie
-Bernard Massie, PhD, graduated in microbiology and immunology from the Université de Montréal in 1982, and completed a three-year postdoctoral fellowship on DNA oncoviruses at McGill University.
He worked at the National Research Council of Canada (NRC) from 1985 to 2019 as a biotechnology researcher, and held various management positions, including Acting Director General of the Centre for Human Health Therapeutics from 2016 to 2019.
He has devoted a significant part of his career to the development of integrated bioprocesses for the industrial production of therapeutic antibodies and adenovirus vaccines. He was also Associate Professor in the Department of Microbiology and Immunology at Université de Montréal from 1998 to 2019. He is currently an independent biotechnology consultant.
He worked at the National Research Council of Canada (NRC) from 1985 to 2019 as a biotechnology researcher, and held various management positions, including Acting Director General of the Centre for Human Health Therapeutics from 2016 to 2019.
He has devoted a significant part of his career to the development of integrated bioprocesses for the industrial production of therapeutic antibodies and adenovirus vaccines. He was also Associate Professor in the Department of Microbiology and Immunology at Université de Montréal from 1998 to 2019. He is currently an independent biotechnology consultant.
